共 219 条
[1]
Siegel RL(2020)Cancer statistics, 2020 CA Cancer J Clin 70 7-30
[2]
Miller KD(2017)Supportive care in pancreatic ductal adenocarcinoma Clin Transl Oncol 19 1293-1302
[3]
Jemal A(2016)Epidemiology of pancreatic cancer World J Gastroenterol 22 9694-9705
[4]
Laquente B(2018)Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes World J Gastroenterol 24 4846-4861
[5]
Calsina-Berna A(2014)Pancreatic adenocarcinoma N Engl J Med 371 1039-1049
[6]
Carmona-Bayonas A(2011)FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 1817-1825
[7]
Jiménez-Fonseca P(2013)Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 1691-1703
[8]
Peiró I(2014)Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine refractory pancreatic cancer: outcomes from the CONKO-003 trial J Clin Oncol 32 2423-2429
[9]
Carrato A(2016)Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial Lancet 387 545-557
[10]
Ilic M(2006)Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study Br J Cancer 94 481-485